Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 213-935-6 | CAS number: 1067-55-6
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Skin sensitisation
Administrative data
- Endpoint:
- skin sensitisation: in vivo (non-LLNA)
- Type of information:
- migrated information: read-across based on grouping of substances (category approach)
- Adequacy of study:
- key study
- Study period:
- 21st October 1986 - 5th December 1986
- Reliability:
- 2 (reliable with restrictions)
- Rationale for reliability incl. deficiencies:
- other: Study conducted in compliance with agreed protocols, with no or minor deviations from standard test guidelines and/or minor methodological deficiencies, which do not affect the quality of the relevant results. Study read across from DBT (2-EHMA).
Data source
Reference
- Reference Type:
- study report
- Title:
- Unnamed
- Year:
- 1 986
- Report date:
- 1986
Materials and methods
Test guideline
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 406 (Skin Sensitisation)
- Deviations:
- no
- GLP compliance:
- yes
- Type of study:
- guinea pig maximisation test
Test material
- Reference substance name:
- DBT (2-EHMA)
- IUPAC Name:
- DBT (2-EHMA)
- Reference substance name:
- 2-ethylhexyl 4,4-dibutyl-10-ethyl-7-oxo-8-oxa-3,5-dithia-4-stannatetradecanoate
- EC Number:
- 234-186-1
- EC Name:
- 2-ethylhexyl 4,4-dibutyl-10-ethyl-7-oxo-8-oxa-3,5-dithia-4-stannatetradecanoate
- Cas Number:
- 10584-98-2
- IUPAC Name:
- 2-ethylhexyl 4,4-dibutyl-10-ethyl-7-oxo-8-oxa-3,5-dithia-4-stannatetradecan-1-oate
- Details on test material:
- - Name of test material (as cited in study report): TK 11638/1
- Substance type: Organotin
- Physical state: Liquid
- Analytical purity: commercial grade
- Main component: dibutyltinbis(2-ethylhexylthioglycolate)
- Impurities (identity and concentrations): NDA
- Composition of test material, percentage of components: NDA
- Storage condition of test material: room temperature
- Batch no.: 1
Constituent 1
Constituent 2
In vivo test system
Test animals
- Species:
- guinea pig
- Strain:
- other: Pirbright White (Tif: DHP)
- Sex:
- male/female
- Details on test animals and environmental conditions:
- TEST ANIMALS
- Source: Ciba-Giegy LTD. Tierfarm, 4344 Sisseln, Switzerland
- Age at study initiation: ca. 10 weeks old
- Weight at study initiation: 266 - 450 g
- Housing: Invividually in Macrolon type 3 cages
- Diet (e.g. ad libitum): ad libitum
- Water (e.g. ad libitum): ad libitum
- Acclimation period: 13th October - 21st October 1986
ENVIRONMENTAL CONDITIONS
- Temperature (°C): 22 ± 3 ºC
- Humidity (%): 30 - 70 %
- Air changes (per hr): NDA
- Photoperiod (hrs dark / hrs light): 12 hours light / 12 hours dark
IN-LIFE DATES: From: 13th October 1986 To: 5th December 1986
Study design: in vivo (non-LLNA)
Inductionopen allclose all
- Route:
- epicutaneous, occlusive
- Vehicle:
- petrolatum
- Concentration / amount:
- 30 % solution in Vaseline vehicle for induction procedure
10 % solution in Vaseline vehicle for 1st challenge procedure
3 % solution in Vaseline vehicle for 2nd challenge procedure
Challengeopen allclose all
- Route:
- epicutaneous, occlusive
- Vehicle:
- petrolatum
- Concentration / amount:
- 30 % solution in Vaseline vehicle for induction procedure
10 % solution in Vaseline vehicle for 1st challenge procedure
3 % solution in Vaseline vehicle for 2nd challenge procedure
- No. of animals per dose:
- 20 (10 male, 10 female)
- Details on study design:
- MAIN STUDY
A. INDUCTION EXPOSURE
The induction was a two-stage operation. First, intradermal adjuvant injections and epidermal closed patch exposure to the test compound in the neck region; second, closed patch exposure over the injection sites one week later.
- First Induction:
0.1 ml of a freshly prepared adjuvant saline mixture (1:1) was injected intracutaneously at 4 sites into the animals neck skin. TK 11638/1 was incorporated in vaseline and applied on a filterpaper patch over the adjuvant injection sites (patch 2x4 cm; occluded administration for 24 hours).
Dose of application: approx. 0.4 g of 30 % TK 11638/1 in vaseiine
- Second Induction:
One week later TK 11638/1 was again incorporated in vaseline and applied on the adjuvant injection sites of the first week. The filterpaper patches were administered occlusively for 48 hours.
Dose of application: approx. 0.4 g paste of 30 % TK 11638/1 in vaseline
B. CHALLENGE EXPOSURE
Two weeks after the epidermal induction application the animals were tested on the flank with TK 11638/1 in vaseline and the vehicle alone (patch 2 x 2 cm; occluded administration for 24 hours).
Dose of application: approx. 0.2 g paste of 10% TK 11638/1 in vaseline. The concentration of the test compound for the induction and challenge periods were determined on separate animals. A second challenge of 3% TK 11638/1 was later performed.
- Control group:
A control group was treated with adjuvant and the vehicle during the induction period. During the challenge period the group was treated with the vehicle as well as with the test compound (at least 10 animals) to control the maximal subirritant concentration of the test compound in adjuvant treated animals. - Challenge controls:
- A control group was treated with adjuvant and the vehicle during the induction period. During the challenge period the group was treated with the vehicle as well as with the test compound (at least 10 animals) to control the maximal subirritant concentration of the test compound in adjuvant treated animals.
- Positive control substance(s):
- no
Study design: in vivo (LLNA)
- Statistics:
- No statistical analysis performed.
Results and discussion
- Positive control results:
- not applicable
In vivo (non-LLNA)
Resultsopen allclose all
- Reading:
- 1st reading
- Hours after challenge:
- 24
- Group:
- test chemical
- Dose level:
- 0.2 g paste at 10 % test substance conc.
- No. with + reactions:
- 20
- Total no. in group:
- 20
- Clinical observations:
- Erythema and Edema formation
- Remarks on result:
- other: Reading: 1st reading. . Hours after challenge: 24.0. Group: test group. Dose level: 0.2 g paste at 10 % test substance conc.. No with. + reactions: 20.0. Total no. in groups: 20.0. Clinical observations: Erythema and Edema formation.
- Reading:
- 2nd reading
- Hours after challenge:
- 48
- Group:
- test chemical
- Dose level:
- 0.2 g paste at 10 % test substance conc.
- No. with + reactions:
- 20
- Total no. in group:
- 20
- Clinical observations:
- Erythema and Edema formation
- Remarks on result:
- other: Reading: 2nd reading. . Hours after challenge: 48.0. Group: test group. Dose level: 0.2 g paste at 10 % test substance conc.. No with. + reactions: 20.0. Total no. in groups: 20.0. Clinical observations: Erythema and Edema formation.
- Reading:
- rechallenge
- Hours after challenge:
- 24
- Group:
- test chemical
- Dose level:
- 0.2 g paste at 3 % test substance conc.
- No. with + reactions:
- 11
- Total no. in group:
- 20
- Clinical observations:
- Erythema and Edema formation
- Remarks on result:
- other: Reading: rechallenge. . Hours after challenge: 24.0. Group: test group. Dose level: 0.2 g paste at 3 % test substance conc.. No with. + reactions: 11.0. Total no. in groups: 20.0. Clinical observations: Erythema and Edema formation.
- Reading:
- rechallenge
- Hours after challenge:
- 48
- Group:
- test chemical
- Dose level:
- 0.2 g paste at 3 % test substance conc.
- No. with + reactions:
- 11
- Total no. in group:
- 20
- Clinical observations:
- Erythema and Edema formation
- Remarks on result:
- other: Reading: rechallenge. . Hours after challenge: 48.0. Group: test group. Dose level: 0.2 g paste at 3 % test substance conc.. No with. + reactions: 11.0. Total no. in groups: 20.0. Clinical observations: Erythema and Edema formation.
- Reading:
- 1st reading
- Hours after challenge:
- 24
- Group:
- test chemical
- Dose level:
- control (0% test material)
- No. with + reactions:
- 0
- Total no. in group:
- 20
- Remarks on result:
- other: Reading: 1st reading. . Hours after challenge: 24.0. Group: test group. Dose level: control (0% test material). No with. + reactions: 0.0. Total no. in groups: 20.0.
Applicant's summary and conclusion
- Interpretation of results:
- sensitising
- Remarks:
- Migrated information
- Conclusions:
- 55% of the animals were sensitized by TK 11638/1 under the experimental conditions employed.
According to the maximization grading TK 11638/1 showed a moderate grade of skin-sensitizing (contact allergenic) potential in albino guinea pigs. - Executive summary:
In a dermal sensitisation study according to OECD 406, 10 week old male and female Pirbright White Guinea Pigs were exposed to TK 11638/1 in a maximisation test. The test substance was found to be sensitising according to 67/548/EEC and should therefore be classified as R43 - May cause sensitisation by skin contact.
It was considered acceptable to read across this study to Dibutyltin dimethoxystannane due to the stuctural similarity with the test substance.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.